Eptifibatide Acetate

한글명:Eptifibatide Acetate

카스 번호148031-34-9

상품명:Eptifibatide Acetate

CBNumberCB7416565

분자식C35H49N11O9S2

포뮬러 무게831.96

MOL 파일148031-34-9.mol

화학적 성질

녹는점	>220°C (dec.)
저장 조건	Refrigerator
용해도	DMSO(약간 용해됨), 메탄올(약간 용해됨), 물(약간 용해됨)
물리적 상태	고체
물리적 상태	단단한 모양
색상	흰색에서 황백색까지
InChIKey	CZKPOZZJODAYPZ-ITVGJGJRNA-N
SMILES	N12CCC[C@H]1C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CCCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1C3C=CC=CC=3NC=1)C2=O)C(N)=O \|&1:4,8,17,33,41,r\|
CAS 데이터베이스	148031-34-9(CAS DataBase Reference)

Eptifibatide Acetate 화학적 특성, 용도, 생산

Indications
Acute Coronary Syndrome (ACS)
INTEGRILIN? is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction (MI) in patients with ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI).
Percutaneous Coronary Intervention (PCI)
INTEGRILIN is indicated to decrease the rate of a combined endpoint of death, new MI, or need for urgent intervention in patients undergoing PCI, including those undergoing intracoronary stenting.
주요 응용
Eptifibatide is a cyclic heptapeptide containing 6 amino acids and 1 mercaptopropionyl (des-amino cysteinyl) residue. An interchain disulfide bridge is formed between the cysteine amide and the mercaptopropionyl moieties. Chemically it is N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-Llysylglycyl-L-α-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic (1→6)-disulfide. Eptifibatide binds to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets and inhibits platelet aggregation.
The eptifibatide peptide is produced by solution-phase peptide synthesis, and is purified by preparative reverse-phase liquid chromatography and lyophilized. The structural formula is:
Dosage forms
Before infusion of INTEGRILIN, the following laboratory tests should be performed to identify pre-existing hemostatic abnormalities: hematocrit or hemoglobin, platelet count, serum creatinine, and PT/aPTT. In patients undergoing PCI, the activated clotting time (ACT) should also be measured.
The activated partial thromboplastin time (aPTT) should be maintained between 50 and 70 seconds unless PCI is to be performed. In patients treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT.

Eptifibatide Acetate 공급 업체

Send Inquriy